Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Yoko Ishigaku"'
Autor:
Mie Shimizu, Tatsunori Natori, Keisuke Tsuda, Makiko Yoshida, Asami Kamada, Kiyotaka Oi, Yoko Ishigaku, Kazumasa Oura, Shinsuke Narumi, Masahiro Yamamoto, Yasuo Terayama
Publikováno v:
Platelets, Vol 31, Iss 3, Pp 360-364 (2020)
Dabigatran, a direct oral thrombin inhibitor, has two therapeutic effects: anticoagulation; and antiplatelet activity. In the clinical field, evaluation of the effect of dabigatran on thrombin-induced platelet aggregation is difficult because of fibr
Externí odkaz:
https://doaj.org/article/e791d7c025634918a588fe4769b9894c
Autor:
Keisuke Tsuda, Yasuo Terayama, Kiyotaka Oi, Shinsuke Narumi, Tetsuya Maeda, Asami Kamada, Kazumasa Oura, Yoko Ishigaku, Mie Shimizu, Tatsunori Natori, Makiko Yoshida
Publikováno v:
Thrombosis Research. 201:123-130
Introduction Dabigatran, a direct thrombin inhibitor, has been widely used in patients with non-valvular atrial fibrillation (NVAF) and is considered to have an antiplatelet effect. However, the mechanisms remain unclear. We evaluated protease-activa
Autor:
Tetsuya Maeda, Mie Shimizu, Makiko Yoshida, Tatsunori Natori, Yoko Ishigaku, Kazumasa Oura, Kiyotaka Oi, Shinsuke Narumi, Keisuke Tsuda, Asami Kamada, Yasuo Terayama
Publikováno v:
Thrombosis Research. 189:1-4
Autor:
Yasuo Terayama, Mie Shimizu, Asami Kamada, Yoko Ishigaku, Makiko Yoshida, Shinsuke Narumi, Kazumasa Oura, Tatsunori Natori, Kiyotaka Oi, Masahiro Yamamoto, Keisuke Tsuda
Publikováno v:
Platelets. 31:360-364
Dabigatran, a direct oral thrombin inhibitor, has two therapeutic effects: anticoagulation; and antiplatelet activity. In the clinical field, evaluation of the effect of dabigatran on thrombin-induced platelet aggregation is difficult because of fibr
Autor:
Mie Shimizu, Keisuke Tsuda, Kiyotaka Oi, Yasuo Terayama, Asami Kamada, Makiko Yoshida, Shinsuke Narumi, Tetsuya Maeda, Ryo Itabashi, Tatsunori Natori, Kazumasa Oura, Yoko Ishigaku
Publikováno v:
Journal of Stroke and Cerebrovascular Diseases. 30:105547
The inhibitory effects of P2Y12 receptor antagonist on PAR1- and PAR4-activating peptide (AP)-induced platelet aggregation have not been fully elucidated. The present study aimed to investigate the inhibitory effects of P2Y12 receptor antagonist on P
Autor:
Shimizu, Mie1,2 (AUTHOR) mie8718@gmail.com, Natori, Tatsunori1 (AUTHOR), Tsuda, Keisuke1 (AUTHOR), Yoshida, Makiko1 (AUTHOR), Kamada, Asami1 (AUTHOR), Oi, Kiyotaka1 (AUTHOR), Ishigaku, Yoko1 (AUTHOR), Oura, Kazumasa1 (AUTHOR), Narumi, Shinsuke1 (AUTHOR), Yamamoto, Masahiro2 (AUTHOR), Terayama, Yasuo1 (AUTHOR)
Publikováno v:
Platelets. 2020, Vol. 31 Issue 3, p360-364. 5p.
Publikováno v:
ECS Meeting Abstracts; 2024, Vol. MA2024-01 Issue 1, p2090-2090, 1p